ライフサイエンスコーパス: deep vein thrombosis

1 , or between extrapulmonary tuberculosis and deep vein thrombosis.

2 t thrombus organization in a murine model of deep vein thrombosis.

3 ation and PAD4 as potential drug targets for deep vein thrombosis.

4 as the source of the prothrombotic effect in deep vein thrombosis.

5 ment of such diseases as atherosclerosis and deep vein thrombosis.

6 ho underwent any lower extremity imaging had deep vein thrombosis.

7 o decrease caval thrombosis in this model of deep vein thrombosis.

8 embolism manifested as pulmonary embolism or deep vein thrombosis.

9 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis.

10 none or placebo stockings) in patients with deep vein thrombosis.

11 al stay less than 2 days, or had preexisting deep vein thrombosis.

12 ng post thrombotic syndrome in patients with deep vein thrombosis.

13 es analysed were mortality and recurrence of deep vein thrombosis.

14 erythrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

15 and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

16 elated bloodstream infection and symptomatic deep-vein thrombosis.

17 The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmon

18 were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterio

19 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1A); use of stress ulcer prophylax

20 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylax

21 evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.

22 ith use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and fi

23 receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TA

24 r and thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2

25 ially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and s

26 common grade three or higher toxicities were deep-vein thrombosis, 57 (26%) of 223 versus 27 (12%) of

27 ffective than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk r

28 for pulmonary embolism, 1% (29 of 2327) for deep vein thrombosis, 7% (61 of 866) for sepsis, 16% (22

29 cal practice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4

30 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrom

31 y status of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% c

32 ge prophylaxis might reduce the frequency of deep-vein thrombosis among high-risk hospitalized patien

33 thrombus and plasma of baboons subjected to deep vein thrombosis, an example of inflammation-enhance

34 The FN rate was 1.14% (8/701; 7 deep vein thrombosis and 1 PE) for pooled normal, very l

35 tional interpretations versus 1.5% (9/585, 5 deep vein thrombosis and 4 PE) in trinary interpretation

36 address this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in pept

37 romboembolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as

38 ontribute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

39 mbolisms occurred, including six symptomatic deep vein thrombosis and four pulmonary emboli, resultin

40 ion, and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thr

41 tect source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

42 In many patients with deep vein thrombosis and pulmonary embolism (venous thro

43 Deep vein thrombosis and pulmonary embolism are major he

44 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

45 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

46 type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-s

47 mber 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assesse

48 ct on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the ev

49 omes and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed b

50 Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, represents

51 Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

52 the mortality and morbidity associated with deep vein thrombosis and pulmonary embolism.

53 ant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

54 ovoked and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

55 ent and included serious adverse events (eg, deep vein thrombosis and systemic complications) and min

56 diagnosis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2

57 n between FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable

58 ostic techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary a

59 pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism

60 he first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data

61 rophylaxis and markedly reduced the rates of deep-vein thrombosis and pulmonary embolism among hospit

62 e comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise ven

63 or the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been sho

64 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecif

65 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

66 ome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembol

67 re hospitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent

68 e events were one event each of hypotension, deep vein thrombosis, and hypophosphatemia.

69 failure, urinary tract infection, pneumonia, deep vein thrombosis, and myocardial infarction were ind

70 ors for venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing

71 ent, respiratory failure, pulmonary embolism/deep vein thrombosis, and sepsis) after selected operati

72 no IVC filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patient

73 physician was alerted to a patient's risk of deep-vein thrombosis, and 1251 patients to a control gro

74 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism

75 ) with an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive antic

76 Preoperative albumin, postoperative deep-vein thrombosis, and electrolyte levels were associ

77 ostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

78 edications included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a st

79 outcome was the composite of any symptomatic deep-vein thrombosis, any nonfatal pulmonary embolism, a

80 Outcomes for graft and deep vein thrombosis are not favorable.

81 ein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of system

82 o difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary emb

83 ration rises more than 100-fold during acute deep vein thrombosis, but there are no prospective data

84 arket and are believed to reduce the risk of deep vein thrombosis by 40%.

85 eduction in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.7

86 high-dose tinzaparin developed a symptomatic deep-vein thrombosis compared with nine assigned aspirin

87 mortality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

88 requently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulan

89 olism up to postoperative day 11, defined as deep-vein thrombosis detected by mandatory bilateral ven

90 e, non-interventional study of patients with deep-vein thrombosis, done in hospitals and community ca

91 8-year-old German-Caucasian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of righ

92 ase-series method to study the risk of first deep vein thrombosis (DVT) (n=7278) and first pulmonary

93 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary emb

94 y embolism (PE), whereas two thirds manifest deep vein thrombosis (DVT) alone.

95 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonar

96 Deep vein thrombosis (DVT) and its complication, pulmona

97 carefully selected patients with cancer with deep vein thrombosis (DVT) and low-risk pulmonary emboli

98 determined the association of Thr312Ala with deep vein thrombosis (DVT) and pulmonary embolism (PE) a

99 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

100 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

101 ratively may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

102 Deep vein thrombosis (DVT) and pulmonary embolism are co

103 Deep vein thrombosis (DVT) and pulmonary embolism are co

104 Monitoring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule

105 Accurate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical pro

106 Asymptomatic deep vein thrombosis (DVT) is a complication of central

107 Deep vein thrombosis (DVT) is a low flow pathology often

108 Deep vein thrombosis (DVT) is a major cause of cardiovas

109 ssessment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge

110 Deep vein thrombosis (DVT) isolated to the calf veins (d

111 Deep vein thrombosis (DVT) occurs in one-quarter of a mi

112 icoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

113 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a

114 ing this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagn

115 Both IPC and GCS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patie

116 luation on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthop

117 (4) deep vein thrombosis (DVT) prophylaxis was independent o

118 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates re

119 Deep vein thrombosis (DVT) resolution represents a speci

120 Deep vein thrombosis (DVT) with its major complication,

121 ght lower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect rela

122 In patients with suspected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS)

123 or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence

124 83 (13.6%) patients; PE, in 237 (11.4%); and deep vein thrombosis (DVT), in 121 (5.8%).

125 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and

126 The incidence rates of grade 3 or higher deep vein thrombosis (DVT), rash, bradycardia, neuropath

127 normal clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive p

128 resolution in humans after acute symptomatic deep vein thrombosis (DVT).

129 t-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT).

130 uperficial thrombosis and the development of deep vein thrombosis (DVT).

131 ated conditions: pulmonary embolism (PE) and deep vein thrombosis (DVT).

132 rtality, all-cause mortality, and subsequent deep vein thrombosis (DVT).

133 The true frequency of deep-vein thrombosis (DVT) during long-haul air travel i

134 The occurrence of deep-vein thrombosis (DVT) in patients with newly diagno

135 Deep-vein thrombosis (DVT) is regarded a chronic disease

136 FVL mutation poses a clearly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

137 ed with SNAC (OHEP/SNAC) in the treatment of deep-vein thrombosis (DVT).

138 mains the gold standard for the diagnosis of deep-vein thrombosis (DVT).

139 hlegmasia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was no

140 o image experimental venous thromboembolism (deep vein thrombosis [DVT]) and pulmonary embolism (PE).

141 Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%.

142 ab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemoth

143 nt (ED(50) = 0.45-0.65 mg/kg) and the rabbit deep vein thrombosis (ED(50) = 0.1-0.4 mg/kg) models.

144 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolis

145 The prevalence of deep vein thrombosis following decannulation from extrac

146 Risk factors for deep-vein thrombosis have been shown not to be always th

147 eral and arterial thrombotic occlusions, and deep vein thrombosis, have been developed and evaluated.

148 ceding week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0

149 also a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1

150 rtions of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thy

151 al [CI], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.0

152 frapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed i

153 Principal outcomes were deep vein thrombosis in both the lower and upper extremi

154 on factors are known to be a risk factor for deep vein thrombosis in humans.

155 measure of relative risk, the odds ratio for deep vein thrombosis in subjects with GlcCer levels belo

156 The prevalence of deep vein thrombosis in the cannulated vessel following

157 describe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults

158 Prophylaxis against deep-vein thrombosis in hospitalized patients remains un

159 onsecutive hospitalized patients at risk for deep-vein thrombosis in the absence of prophylaxis.

160 was symptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embo

161 right-sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95

162 were significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared wit

163 The use of thrombolysis for occlusive deep vein thrombosis, in attempt to reduce the long-term

164 y disseminated intravascular coagulation and deep vein thrombosis, in tuberculosis (TB) patients.

165 , 2.22; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% co

166 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or

167 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients

168 ltrate the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue

169 Deep vein thrombosis is a major global health issue, res

170 e of symptomatic central venous line-related deep vein thrombosis is associated with worse outcomes,

171 treatment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States

172 Serial testing for proximal deep-vein thrombosis is a safe and effective alternative

173 Objective testing for proximal deep-vein thrombosis is useful in patients with suspecte

174 thic VTE, including those with isolated calf deep vein thrombosis, is safe and effective.

175 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the add

176 h-dose tinzaparin was superior in preventing deep-vein thrombosis, it was associated with a higher ra

177 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic

178 pulmonary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 m

179 redictors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paral

180 onary artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-react

181 mortality in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

182 (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and

183 y adverse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2

184 (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), and clotted devices (n =

185 efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or al

186 ts (catheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, ble

187 Deep vein thrombosis occurred in 5 patients.

188 Severe peripheral neuropathy and deep-vein thrombosis occurred more frequently in the tha

189 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

190 s Seminar, we discuss pulmonary embolism and deep vein thrombosis of the legs.

191 mbolism is strongly associated with proximal deep-vein thrombosis of the legs (popliteal, femoral, or

192 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respective

193 us thromboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary emb

194 A FN study was defined as development of deep vein thrombosis or PE within 3 months after a negat

195 y, independent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time o

196 If deep vein thrombosis or pulmonary embolism is diagnosed,

197 with inflammatory bowel disease who develop deep vein thrombosis or pulmonary embolism often have ac

198 Deep vein thrombosis or pulmonary embolism were determin

199 Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovok

200 dy outcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurre

201 or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respira

202 (ie, one or more dose received, presence of deep vein thrombosis or pulmonary embolism, or assessmen

203 role of dietary intake in the development of deep vein thrombosis or pulmonary embolus (venous thromb

204 duration of follow-up, and thrombosis type (deep vein thrombosis or pulmonary embolus).

205 with emboli in these small vessels may have deep vein thrombosis or recurrent emboli.

206 onfirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary

207 ged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embo

208 The computer alert reduced the risk of deep-vein thrombosis or pulmonary embolism at 90 days by

209 estimates of the likelihood of freedom from deep-vein thrombosis or pulmonary embolism at 90 days we

210 clinically diagnosed, objectively confirmed deep-vein thrombosis or pulmonary embolism at 90 days.

211 oagulant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9

212 ated use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed

213 cial-vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression

214 icacy outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression

215 3] vs 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [

216 Cs were associated with an increased risk of deep vein thrombosis (OR 2.55, 1.54-4.23, p<0.0001) but

217 n of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults we

218 nd collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

219 botic events (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorr

220 mboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-

221 bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonar

222 ath (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

223 laxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0

224 tiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft thrombosis, collag

225 arly antithrombotics (91.46% versus 97.04%), deep vein thrombosis prophylaxis (73.79% versus 89.54%),

226 95% confidence interval [CI], 0.77 to 0.91), deep vein thrombosis prophylaxis (OR, 0.88; 95% CI, 0.83

227 ic compression (IPC) is an effective form of deep vein thrombosis prophylaxis for general surgery pat

228 flow, improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall pe

229 management, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic inte

230 oley catheter removal, R = -0.089 [P = .63]; deep vein thrombosis prophylaxis, R = 0.101 [P = .59]).

231 Measure documentation, lipid management, and deep vein thrombosis prophylaxis.

232 ts with severe sepsis should be treated with deep-vein thrombosis prophylaxis.

233 ient ischemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism, and other syst

234 edical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia)

235 s of acute renal failure requiring dialysis, deep vein thrombosis, pulmonary embolism, sepsis, pneumo

236 he composite secondary end point of proximal deep-vein thrombosis, pulmonary embolism, and death (2.7

237 ring the first 3 weeks symptomatic recurrent deep vein thrombosis-pulmonary embolism (DVT/PE) occurre

238 rade 3 to 5 nonhematologic toxicity included deep vein thrombosis/pulmonary embolism (21%), hemorrhag

239 ively), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%)

240 With the baseline PICC-related deep vein thrombosis rate of 2.7% and pooled OR of 2.55,

241 oled RR, 4.30 95% CI, 1.60-11.54) and higher deep vein thrombosis rates (2.94 1.35-6.38).

242 ransgenic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate

243 analysis of 11 studies comparing the risk of deep vein thrombosis related to PICCs with that related

244 ophylaxis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-

245 o significant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-

246 Deep vein thrombosis remains a major health problem nece

247 of post thrombotic syndrome in patients with deep vein thrombosis remains unknown.

248 fibrillation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasi

249 28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.

250 CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.

251 , 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.

252 clinical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion aft

253 Deep vein thrombosis screening was performed using a rig

254 6 patients (32%), and the most frequent were deep vein thrombosis (six patients), constipation (four

255 re observed in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary s

256 rimary efficacy outcome was the composite of deep-vein thrombosis (symptomatic or asymptomatic detect

257 the composite of symptomatic or asymptomatic deep vein thrombosis, symptomatic pulmonary embolism, or

258 PICCs are associated with a higher risk of deep vein thrombosis than are CVCs, especially in patien

259 s significantly more effective in preventing deep-vein thrombosis than 30 mg of enoxaparin twice dail

260 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical

261 o cases), pulmonary embolus (two cases), and deep-vein thrombosis (three cases).

262 ly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation a

263 cal trial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter

264 haracterization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic s

265 Upper-extremity deep vein thrombosis (UEDVT) occurs spontaneously or som

266 Deep-vein thrombosis underlies this disorder.

267 in the thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokine

268 omputed tomography combined with testing for deep vein thrombosis using compression ultrasonography w

269 All women who had a recorded diagnosis of deep-vein thrombosis, venous thrombosis not otherwise sp

270 dies, the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were cr

271 Deep vein thrombosis was induced in the inferior vena ca

272 h comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure

273 mptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twi

274 screened high-risk patients, 20 asymptomatic deep vein thrombosis were detected with venous duplex ul

275 21 years, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasou

276 ptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban

277 d anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory mo